Cover Image
市場調查報告書

後葡萄膜炎:開發平台分析

Posterior Uveitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321929
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
後葡萄膜炎:開發平台分析 Posterior Uveitis - Pipeline Review, H2 2016
出版日期: 2016年10月30日 內容資訊: 英文 65 Pages
簡介

葡萄膜炎是眼睛的鞏膜和視網膜間的葡萄膜腫起、發炎的疾病。其中之一就是後葡萄膜炎,其症狀有視力模糊、視野中有漂移的黑塊、眼痛、眼睛充血、對光過敏等。因素有發炎、自體免疫疾病、眼球的受傷病史等。治療方法有給予類固醇點眼藥,抗發炎藥,抗生素,抗病毒藥物。

本報告提供後葡萄膜炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

後葡萄膜炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • ForSight VISION4, Inc.
  • Neuroptis Biotech
  • pSivida Corp.
  • Regeneron Pharmaceuticals, Inc.
  • Virogenomics, Inc.
  • XOMA Corporation

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • fluocinolone acetonide
  • gevokizumab
  • NOP-3
  • Peptides to Modulate TCR for Uveitis
  • sarilumab
  • V-404

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8626IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Posterior Uveitis - Pipeline Review, H2 2016, provides an overview of the Posterior Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Posterior Uveitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively.Posterior Uveitis.

Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Posterior Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Posterior Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Posterior Uveitis Overview
  • Therapeutics Development
    • Pipeline Products for Posterior Uveitis - Overview
  • Posterior Uveitis - Therapeutics under Development by Companies
  • Posterior Uveitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Posterior Uveitis - Products under Development by Companies
  • Posterior Uveitis - Companies Involved in Therapeutics Development
    • Aciont Inc.
    • Neuroptis Biotech
    • Oculis ehf
    • pSivida Corp.
    • Regeneron Pharmaceuticals Inc
    • Sandoz International GmbH
    • Santen Pharmaceutical Co., Ltd.
  • Posterior Uveitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone sodium phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EYS-606 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluocinolone acetonide SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sarilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Posterior Uveitis - Dormant Projects
  • Posterior Uveitis - Discontinued Products
  • Posterior Uveitis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target
      • Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting
      • Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle
      • Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)
      • Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
      • May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
      • Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis
      • Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
      • Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis
      • Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
      • May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis
      • Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis
      • Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Posterior Uveitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Posterior Uveitis - Pipeline by Aciont Inc., H2 2016
  • Posterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016
  • Posterior Uveitis - Pipeline by Oculis ehf, H2 2016
  • Posterior Uveitis - Pipeline by pSivida Corp., H2 2016
  • Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Posterior Uveitis - Pipeline by Sandoz International GmbH, H2 2016
  • Posterior Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Posterior Uveitis - Dormant Projects, H2 2016
  • Posterior Uveitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Posterior Uveitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top